Acceptance of Reduced-Risk Drinking as a Therapeutic Goal within the Polish Alcohol Treatment System, Alcohol and Alcoholism, vol.3, issue.4, pp.436-477, 2016. ,
DOI : 10.1111/j.1360-0443.1986.tb00355.x
Differences in the acceptability of non-abstinence goals by type of drug among American substance abuse clinicians, Journal of Substance Abuse Treatment, vol.46, issue.2, pp.214-222, 2014. ,
DOI : 10.1016/j.jsat.2013.07.005
Assessment report: Selincro? international non-proprietory name: nalmefene. EMA/ 78844 Available at, 2012. ,
Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency, BMJ, vol.348, issue.mar10 21, p.2017, 2014. ,
DOI : 10.1136/bmj.g2017
Bad medicine: nalmefene in alcohol misuse, BMJ, vol.348, issue.feb14 1, p.1531, 2014. ,
DOI : 10.1136/bmj.g1531
Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers, Addiction, vol.2, issue.8, pp.1477-87, 2016. ,
DOI : 10.1371/journal.pmed.0020138
Evaluation in alcohol use disorders ??? insights from the nalmefene experience, BMC Medicine, vol.353, issue.3, p.119, 2016. ,
DOI : 10.1111/j.1530-0277.2008.00682.x
URL : https://hal.archives-ouvertes.fr/hal-01380423
Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials, PLOS Medicine, vol.48, issue.12, p.1001924, 2015. ,
DOI : 10.1371/journal.pmed.1001924.s004
URL : https://hal.archives-ouvertes.fr/hal-01255842
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, PharmacoEconomics, vol.80, issue.8, pp.833-880, 2015. ,
DOI : 10.1111/j.1360-0443.1985.tb05288.x
Efficacy and Tolerability of Naltrexone in the Management of Alcohol Dependence, Current Pharmaceutical Design, vol.16, issue.19, pp.2091-2098, 2010. ,
DOI : 10.2174/138161210791516459
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore, Alimentary Pharmacology & Therapeutics, vol.12, issue.Suppl 7, pp.865-82, 2017. ,
DOI : 10.1111/j.1521-0391.2003.tb00543.x
Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies, CNS Neuroscience & Therapeutics, vol.103, issue.2, pp.25-37 ,
DOI : 10.1371/journal.pone.0129289
URL : https://hal.archives-ouvertes.fr/hal-01276028
Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision, The World Journal of Biological Psychiatry, vol.22, issue.6, pp.86-119, 2017. ,
DOI : 10.1097/JCP.0000000000000209
A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective, The Lancet, vol.389, issue.10078, pp.1558-80, 2017. ,
DOI : 10.1016/S0140-6736(16)32420-5
The alcohol withdrawal syndrome, The Lancet, vol.349, issue.9069, pp.1897-900, 1997. ,
DOI : 10.1016/S0140-6736(97)04572-8
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis, JAMA, vol.311, pp.1889-900, 2014. ,
Comparing Nalmefene and naltrexone in alcohol dependence: are there any differences? Results from an indirect meta-analysis, Pharmacopsychiatry, vol.49, pp.66-75, 2016. ,
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, vol.343, issue.oct18 2, p.5928, 2011. ,
DOI : 10.1136/bmj.d5928
Cochrane handbook for systematic reviews of interventions. Cochrane Collaboration. Version 5.1.0. Available at: http://handbook-5-1.cochrane. org/ (accessed 23, 2017. ,
R: a Language and Environment for Statistical Computing Vienna: R Foundation for Statistical Computing, 2009. ,
general package for meta-analysis, version 3 Available at: https://cran.r-project, pp.6-6, 2014. ,
Network meta-analysis using frequentist methods. R package version 0.8-0, 2015. (Available at: https://cran.r-project, 2017. ,
Conducting meta-analyses in R with the metafor package Available at: http://www.jstatsoft.org/v36, J Stat Softw, vol.36, issue.i03, pp.1-48, 2010. ,
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, Journal of Clinical Epidemiology, vol.62, issue.10, pp.1-34, 2009. ,
DOI : 10.1016/j.jclinepi.2009.06.006
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations, Annals of Internal Medicine, vol.162, issue.11, pp.777-84, 2015. ,
DOI : 10.7326/M14-2385
Beta blockade during and after myocardial infarction: An overview of the randomized trials, Progress in Cardiovascular Diseases, vol.27, issue.5, pp.335-71, 1985. ,
DOI : 10.1016/S0033-0620(85)80003-7
Network meta-analysis, electrical networks and graph theory, Research Synthesis Methods, vol.10, issue.4, pp.312-336, 2012. ,
DOI : 10.1111/j.1469-1809.1940.tb02257.x
Ranking treatments in frequentist network meta-analysis works without resampling methods, BMC Medical Research Methodology, vol.17, issue.2, p.58, 2015. ,
DOI : 10.1016/j.jval.2014.01.004
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials, BMJ, vol.343, issue.jul22 1, p.4002, 2011. ,
DOI : 10.1136/bmj.d4002
Evaluating the Quality of Evidence from a Network Meta-Analysis, PLoS ONE, vol.67, issue.6, p.99682, 2014. ,
DOI : 10.1371/journal.pone.0099682.s003
A Multi-site Dose Ranging Study of Nalmefene in the Treatment of Alcohol Dependence, Journal of Clinical Psychopharmacology, vol.24, issue.4, pp.421-429, 2004. ,
DOI : 10.1097/01.jcp.0000130555.63254.73
A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence, European Neuropsychopharmacology, vol.23, issue.11, pp.1432-1474, 2013. ,
DOI : 10.1016/j.euroneuro.2013.02.006
Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double-Blind Placebo-Controlled Multicenter Study, Alcoholism: Clinical and Experimental Research, vol.22, issue.7, pp.1179-87, 2007. ,
DOI : 10.1111/j.1530-0277.2002.tb02486.x
Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene, Biological Psychiatry, vol.73, issue.8, pp.706-719, 2013. ,
DOI : 10.1016/j.biopsych.2012.10.020
A Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCI for Alcohol Dependence, Alcoholism: Clinical and Experimental Research, vol.33, issue.5, pp.1162-1169, 1994. ,
DOI : 10.1001/archpsyc.1976.01770060086012
A Double-blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence, Archives of General Psychiatry, vol.56, issue.8, pp.719-743, 1999. ,
DOI : 10.1001/archpsyc.56.8.719
Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study, Journal of Psychopharmacology, vol.80, issue.8, pp.733-777, 2014. ,
DOI : 10.1016/j.euroneuro.2011.07.018
Naltrexone for alcohol-dependent patients, Irish Journal of Medical Science, vol.139, issue.1, pp.34-37, 2004. ,
DOI : 10.1007/978-1-4612-0357-5_3
Gabapentin Combined With Naltrexone for the Treatment of Alcohol Dependence, American Journal of Psychiatry, vol.168, issue.7, pp.709-726, 2011. ,
DOI : 10.1176/appi.ajp.2011.10101436
Naltrexone plus aripiprazole compared to naltrexone alone and placebo in the treatment of alcohol dependence? a double blind pilot study, Neuropsychopharmacology, vol.36, pp.234-239, 2011. ,
Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers, Addictive Behaviors, vol.29, issue.6, pp.1253-1261, 2004. ,
DOI : 10.1016/j.addbeh.2004.03.027
Targeted Use of Naltrexone Without Prior Detoxification in the Treatment of Alcohol Dependence: A Factorial Double-Blind, Placebo-Controlled Trial, Journal of Clinical Psychopharmacology, vol.21, issue.3, pp.287-92, 2001. ,
DOI : 10.1097/00004714-200106000-00006
Effectiveness of Naltrexone in a Community Treatment Program, Alcoholism: Clinical & Experimental Research, vol.54, issue.17, pp.1710-1717, 2004. ,
DOI : 10.1016/0197-2456(88)90048-7
Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial, Neuropsychopharmacology, vol.22, issue.5, pp.493-503, 2000. ,
DOI : 10.1016/S0893-133X(99)00135-9
Targeted Naltrexone for Early Problem Drinkers, Journal of Clinical Psychopharmacology, vol.23, issue.3, pp.294-304, 2003. ,
DOI : 10.1097/01.jcp.0000084030.22282.6d
Targeted Naltrexone for Problem Drinkers, Journal of Clinical Psychopharmacology, vol.29, issue.4, pp.350-357, 2009. ,
DOI : 10.1097/JCP.0b013e3181ac5213
URL : http://europepmc.org/articles/pmc3184851?pdf=render
A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men., Journal of Consulting and Clinical Psychology, vol.80, issue.5, pp.863-75, 2012. ,
DOI : 10.1037/a0028615
Naltrexone for alcohol dependence: a randomized controlled trial, Addiction, vol.96, issue.11, pp.1565-73, 2001. ,
DOI : 10.1046/j.1360-0443.2001.961115654.x
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebocontrolled , randomized clinical trial of efficacy and safety, J Clin Psychiatry, vol.76, pp.207-220, 2015. ,
A Placebo-Controlled Randomized Clinical Trial of Naltrexone in the Context of Different Levels of Psychosocial Intervention, Alcoholism: Clinical and Experimental Research, vol.33, issue.Suppl. 2, pp.1299-308, 2008. ,
DOI : 10.1001/archpsyc.1997.01830200071010
Moderators of Naltrexone???s Effects on Drinking, Urge, and Alcohol Effects in Non-Treatment-Seeking Heavy Drinkers in the Natural Environment, Alcoholism: Clinical and Experimental Research, vol.44, issue.99, pp.58-66, 2008. ,
DOI : 10.1001/archpsyc.1992.01820110040006
Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation, Journal of Psychiatric Research, vol.40, issue.5, pp.383-93, 2006. ,
DOI : 10.1016/j.jpsychires.2006.02.002
BACLOFEN EFFICACY IN REDUCING ALCOHOL CRAVING AND INTAKE: A PRELIMINARY DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY, Alcohol and Alcoholism, vol.37, issue.5, pp.504-512, 2002. ,
DOI : 10.1093/alcalc/37.5.504
Dose-Response Effect of Baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial, Alcohol and Alcoholism, vol.22, issue.1, pp.312-319, 2011. ,
DOI : 10.1111/j.1530-0277.2006.00259.x
Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial, Alcoholism: Clinical and Experimental Research, vol.12, issue.11, pp.1849-57, 2010. ,
DOI : 10.1001/archpsyc.1965.01720310065008
Baclofen as Add-On to Standard Psychosocial Treatment for Alcohol Dependence: a Randomized, Double-Blind, Placebo-Controlled Trial With 1Year Follow-Up, Journal of Substance Abuse Treatment, vol.52, pp.24-30, 2015. ,
DOI : 10.1016/j.jsat.2014.11.007
Oral topiramate for treatment of alcohol dependence: a randomised controlled trial, The Lancet, vol.361, issue.9370, pp.1677-85, 2003. ,
DOI : 10.1016/S0140-6736(03)13370-3
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>, JAMA, vol.298, issue.14, pp.1641-51, 2007. ,
DOI : 10.1001/jama.298.14.1641
Zonisamide, Topiramate, and Levetiracetam, Journal of Clinical Psychopharmacology, vol.35, issue.1, pp.34-42, 2015. ,
DOI : 10.1097/JCP.0000000000000246
URL : http://pdfs.journals.lww.com/psychopharmacology/2015/02000/Zonisamide,_Topiramate,_and_Levetiracetam_.6.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1505464132025;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzd8ygtSAfJbMLiEzuzQRKgPeapD+wVqp9AKZBxPtOVS/sxrzBAlrfUrywBi3pwvth4;hash|xd8N1YaMzFs3+PQgCR8gsA==
Polymorphism, American Journal of Psychiatry, vol.171, issue.4, pp.445-52, 2014. ,
DOI : 10.1176/appi.ajp.2013.13081014
Safety and Efficacy of Baclofen in the Treatment of Alcohol-Dependent Patients, Current Pharmaceutical Design, vol.16, issue.19, pp.2113-2120, 2010. ,
DOI : 10.2174/138161210791516440
Demystifying trial networks and network meta-analysis, BMJ, vol.346, issue.may14 2, p.2914, 2013. ,
DOI : 10.1136/bmj.f2914
URL : http://www.bmj.com/content/bmj/346/bmj.f2914.full.pdf
The COMET Initiative database: progress and activities update (2015), Trials, vol.383, issue.9912, p.54, 2015. ,
DOI : 10.1016/S0140-6736(13)62227-8
Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers, BMC Medicine, vol.31, issue.1, p.159, 2013. ,
DOI : 10.1002/sim.5442
Nalmefene for reducing alcohol consumption in people with alcohol dependence: evaluation report Available at: https:// www.nice.org.uk/guidance/ta325?, pp.3629887952016-628192516, 2014. ,
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin?, Pharmacopsychiatry, vol.49, issue.06, pp.260-261, 2016. ,
DOI : 10.1055/s-0042-110493
Off-Label Baclofen Prescribing Practices among French Alcohol Specialists: Results of a National Online Survey, PLoS ONE, vol.7, issue.302, p.98062, 2014. ,
DOI : 10.1371/journal.pone.0098062.t003
Recommendations of French Alcohol Society and European Federation of Addiction Societies, CNS Neuroscience & Therapeutics, vol.119, issue.6, pp.535-541, 2016. ,
DOI : 10.1177/1062860616631822
Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment, Expert Opinion on Drug Safety, vol.37, issue.3, pp.747-51, 2016. ,
DOI : 10.1111/cns.12489
The ???Temporary Recommendations for Use???: A dual-purpose regulatory framework for off-label drug use in France, Health Policy, vol.119, issue.11, pp.1399-405, 2015. ,
DOI : 10.1016/j.healthpol.2015.09.003
Severity of Deliberate Acute Baclofen Poisoning: A Nonconcurrent Cohort Study, Basic & Clinical Pharmacology & Toxicology, vol.359, issue.4, pp.360-364, 2014. ,
DOI : 10.1016/S0140-6736(02)07500-1
Baclofen and alcohol use disorders: From miracle to mirage, European Neuropsychopharmacology, vol.27, issue.7, pp.691-693, 2017. ,
DOI : 10.1016/j.euroneuro.2017.05.003
Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy, Epilepsy & Behavior, vol.6, issue.3, pp.373-81, 2005. ,
DOI : 10.1016/j.yebeh.2005.01.002
Reporting of safety data from randomised trials, The Lancet, vol.352, issue.9142, pp.1752-1755, 1998. ,
DOI : 10.1016/S0140-6736(05)79825-1